33608-08-1Relevant academic research and scientific papers
Chemoselective reduction of aldehydes: Via a combination of NaBH4 and acetylacetone
Sui, Guoqing,Lv, Qingyun,Song, Xiaoqing,Guo, Huihui,Dai, Jiatong,Ren, Li,Lee, Chi-Sing,Zhou, Wenming,Hao, Hong-Dong
supporting information, p. 15793 - 15796 (2019/10/19)
A bench-stable combination of NaBH4-acetylacetone was developed for the efficient chemoselective reduction of aldehydes in the presence of ketones. This method offers a useful synthetic protocol for distinguishing carbonyl reaction sites, and its synthetic utility is reflected by its moisture tolerance and high efficiency in a variety of complex settings.
COMPOSITIONS COMPRISING TRITERPENOIDS AND USES THEREOF FOR TREATING OPTIC NEUROPATHY
-
Page/Page column 86; 88; 89, (2018/03/28)
The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating optic neuropathy conditions.
COMPOSITIONS COMPRISING TRITERPENOIDS
-
Page/Page column 84; 85, (2017/04/11)
The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating for use in treating a condition selected from Alzheimer's disease (AD), Parkinson's Diseases (PD) and vascular dementia (VD).
Synthesis and biological evaluation of oleanolic acid derivatives as antitumor agents
Chen, Lei,Wu, Jian-Bo,Lei, Fan,Qian, Shan,Hai, Li,Wu, Yong
, p. 355 - 363 (2012/08/29)
Derivatives of oleanolic acid were synthesized and evaluated in vitro for their growth inhibition against human hepatocellular carcinoma cell line (HepG2) and colon cancer cell line (Col-02). Several derivatives exhibited moderate-to-good inhibitory activity, with 3 displaying the most promising inhibition [GI50=1.75μM (HepG2), 0.71μM (Col-02)]. Structure-activity relationship analyses of these derivatives demonstrated that a 1-en-2-cyano-3-oxo in ring A and a nitro at C-17 were important in retention of the inhibition against HepG2 and Col-02 cells.
